ALK and lymphoma: We report the characterization of the first CTLC-ALK positive DLBCL cell line (LM1), the establishment of a pre-clinical model to study the role of CLTC-ALK activity in DLBCL lymphomagenesis, and demonstrate that these lymphomas display activation of ALK signalling pathways and are potently suppressed in vitro and in vivo by a selective ALK inhibitor.